66315-16-0

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-amino-4-(methylamino)benzenecarboxylate is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Dye Industry:
In the dye industry, Methyl 3-amino-4-(methylamino)benzenecarboxylate is utilized as a precursor in the production of various dyes, leveraging its aromatic and functional groups to create a range of colorants for different applications.
Used in Organic Chemistry Research:
Methyl 3-amino-4-(methylamino)benzenecarboxylate is employed as a building block in organic chemistry research, facilitating the creation of a wide array of organic compounds for various purposes, including the development of new materials and chemical processes.

Upstream product

• 22907-68-2 3,4-dinitrobenzoic acid methyl ester 
• 41263-74-5 4-(methylamino)-3-nitrobenzoic acid 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 36242-50-9 4-methylamino-3-nitro-benzoic acid methyl ester 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 

Downstream Products

• 794513-97-6 methyl 3-((2-(tert-butoxycarbonylamino)ethyl)carbonyl)amino-4-methylaminobenzoate 
• 131020-36-5 methyl 1-methyl-1H-benzo[d]imidazole-5-carboxylate 
• 396652-38-3 methyl 1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate 
• 794513-93-2 methyl 3-((4-nitro-1-methylpyrrole-2-yl)carbonyl)amino-4-methylaminobenzoate 
• 1219121-47-7 2-(2,6-Difluoro-phenylamino)-1-methyl-1H-benzoimidazole-5-carboxylic acid ethyl ester 
• 1242267-88-4 methyl 2-(chloromethyl)-1-methylbenzimidazole-5-carboxylate 
• 305381-67-3 1-methyl-1H-benzo[d][1,2,3]triazole-5-carboxylic acid 
• 499785-52-3 ethyl 1-methyl-1H-benzo[d][1,2,3]triazole-5-carboxylate 
• 423768-38-1 1-methyl-1H-1,2,3-benzotriazole-5-carbonyl chloride 
• 66630-73-7 1-methyl-2-phenyl-1H-benzo[d]imidazole-5-carboxylic acid 

Relevant academic research and scientific papers

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors

We describe the synthesis of a series of 2-arylbenzimidazole derivatives bearing sulfonamide functionality (4a–d, 7a–c and 10) as well as hydroxamic acid (15a–b), carboxylic acid (16a–b), carboxamide (17a–b) and boronic acid (22a–b and 26) functionalities, which act as human carbonic anhydrase (hCA, EC 4.2.1.1) inhibitors. The newly synthesized benzimidazole derivatives were evaluated against 4 physiologically relevant CA isoforms (hCA I, II, IX, and XII), and especially the sulfonamide-containing benzimidazoles demonstrated intriguing inhibitory activity against tumor associated CA IX and XII with KI values in the range of 5.2–29.3 nM and 9.9–41.7 nM, respectively. Notably, compound 4c was the most potent and selective CA IX (KI = 6.6 nM) and XII (KI = 9.9 nM) inhibitor with a significant selectivity ratio over cytosolic CA I and II isoforms in the range of 3.4–25.2. In addition, compounds having hydroxamic acid (15a-b) or carboxylic acid (16a-b) functionalities resulted in greater selectivity ratios for CA IX/XII over CAI/II in the range of 4.1–121.5 although with KI values in lower micromolar potency (KIs = 0.36–0.85 μM for CA IX/XII).

STING AGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.

COVALENT INHIBITORS OF PAD4

The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

The discovery of new scaffold of plant activators: From salicylic acid to benzotriazole

Started from salicylic acid (SA) and related commercialized plant activators, based on molecular three-dimensional shape and pharmacophore similarity comparison (SHAFTS), a new lead compound benzotriazole was predicted and a series of benzotriazole derivatives were designed and synthesized. The bioassay showed that benzotriazole had high activity against a broad spectrum of diseases including fungi and oomycetes in vivo, but no activity in vitro. And the introduction of proper groups at the 1’-position and 5’-position was beneficial to the activity. So, they had the potential to be exploited as novel plant activators.

BICYCLIC INHIBITORS OF PAD4

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

HETEROARYL INHIBITORS OF PAD4

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Substituted Pyran Derivatives

Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter system

SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES

The present invention relates to substituted benzimidazoles, benzothiazoles and benzoxazoles, processes for their preparation, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS

The present invention relates to compounds of general formula (I) in which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.